Related Experiment Videos
Prolonged neuromuscular block associated with mivacurium
British Journal of Anaesthesia
|February 1, 1995
Summary
Mivacurium, a short-acting neuromuscular blocker, can cause prolonged effects in children with undiagnosed plasma cholinesterase deficiency. This highlights the importance of screening for this enzyme deficiency before administering certain anesthetic agents.
Area of Science:
- Anesthesiology
- Pharmacology
- Biochemistry
Background:
- Mivacurium is a short-acting, nondepolarizing neuromuscular blocker used for tracheal intubation.
- Its efficacy is comparable to suxamethonium for short procedures.
- Metabolism relies on plasma cholinesterase, similar to suxamethonium.
Observation:
- A case study involving a child experiencing unexpected prolonged neuromuscular block.
- The child had a previously undiagnosed deficiency in plasma cholinesterase activity.
Findings:
- Reduced plasma cholinesterase activity significantly prolongs the duration of action for mivacurium.
- This can lead to unexpected and extended neuromuscular blockade in susceptible individuals.
Implications:
- Plasma cholinesterase deficiency should be considered in pediatric patients undergoing procedures requiring neuromuscular blockers.
- Screening for enzyme deficiency may be warranted to prevent prolonged neuromuscular blockade.
- This case underscores the importance of understanding individual metabolic variations in anesthetic drug response.